BioStem director gets 7,671 shares from RSUs
BioStem Technologies, Inc. (BSEM) director Rayna Lesser Hannaway reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) director Rayna Lesser Hannaway reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to one share and vested on that date, with no cash exercise price reported. Following the transaction, Hannaway directly holds 7,671 common shares and no remaining RSUs from this grant.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 7,671 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,671 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2. These restricted stock units vested on August 27, 2026.
Key Figures
Key Terms
Restricted Stock Units financial
derivative security financial
Form 4 regulatory
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BSEM director Rayna Lesser Hannaway report on this Form 4?
What happened to the 7,671 Restricted Stock Units reported for BSEM?
Was the BSEM Form 4 transaction an open-market buy or sell?
Did the BioStem Technologies (BSEM) Form 4 indicate use of a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.